This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Swine Flu Biotech Bubble Primed to Burst

To win government approval, a company must prove that it has a safe product that does at least as good a job at protecting people from the flu as what's already on the market -- no matter the flu strain, whether pig or bird or some deadly combination. Such proofs demand human clinical trials on the scale of more than 5,000 and as many as 30,000 people.

"It's a long drawn-out process, man," says Vijay Samant, CEO of Vical, a company not unfamiliar with the hyping of swine-flu vaccines. "It's like the reincarnation of Buddha: You can't get tempted by wine, women and food. If you do, you'll get sent back to the end of the line."

No biotech that has touted its non-traditional approach to influenza vaccination is anywhere close to starting a clinical trial of that size. Nor has any firm really demonstrated the kind of efficacy for its vaccines that would convince anyone that profits will be forthcoming even next year or the year after that.

Take Novavax, the Maryland developer whose vaccine is based on cell-culture technology, an alternative to egg-based vaccines that many companies have been attempting to develop, including the likes of Novartis and Baxter. A recent press release from the Maryland firm highlights the difficulty in determining up from down in the heady world of vaccine research, and how investors can get caught up in a thicket of complexity.

Novavax in this press release announced the conclusion of a phase II clinical trial of its vaccine, a study that looked at the immune response produced in 221 people against the three influenza strains that the Center for Disease Control had determined were the most dangerous last year. (These strains, chosen by the CDC for the 2008-09 flu season, did not therefore include currently circulating swine flu.)

On the surface, the results for Novavax appeared reasonable enough. But the company left out some crucial information: the immune response produced in the study's small control group of just 20 people, each of whom received a dose of Sanofi's Fluzone vaccine.

3 of 6

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs